GURUFOCUS.COM » STOCK LIST » Europe » Germany » HAM » Biogen Inc (HAM:IDP) » Definitions » FCF Yield %
Switch to:

Biogen (HAM:IDP) FCF Yield %

: 3.81 (As of Today)
View and export this data going back to 2001. Start your Free Trial

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Biogen's Trailing 12-Month Free Cash Flow is €1,152 Mil, and Market Cap is €29,991 Mil. Therefore, Biogen's FCF Yield % for today is 3.81%.

The historical rank and industry rank for Biogen's FCF Yield % or its related term are showing as below:

HAM:IDP' s FCF Yield % Range Over the Past 10 Years
Min: -3.57   Med: 5.33   Max: 15.75
Current: 3.81


During the past 13 years, the highest FCF Yield % of Biogen was 15.75%. The lowest was -3.57%. And the median was 5.33%.

HAM:IDP's FCF Yield % is ranked better than
74.84% of 1093 companies
in the Drug Manufacturers industry
Industry Median: -0.86 vs HAM:IDP: 3.81

Biogen's FCF Margin % for the quarter that ended in Dec. 2023 was -2.21%.


Biogen FCF Yield % Historical Data

The historical data trend for Biogen's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.41 9.99 9.37 2.92 3.34

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 3.93 3.93 5.37 -0.57

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen FCF Yield % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Biogen's FCF Yield % falls into.



Biogen FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Biogen's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=1133.228 / 33964.56
=3.34%

Biogen's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-48.326 * 4 / 33964.56
=-0.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Biogen FCF Yield % Related Terms

Thank you for viewing the detailed overview of Biogen's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines